Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Esser

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
Science Translational Medicine|December 21, 2022
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccineLauren A Chang, Emily Phung, Michelle C Crank, et al.
The New England Journal of Medicine|July 30, 2020
Single-Dose Nirsevimab for Prevention of RSV in Preterm InfantsM Pamela Griffin, Yuan Yuan, Therese Takas, et al.
Clinical and Vaccine Immunology : CVI|March 27, 2009
Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigenMichael D Raedler, Samantha Heyne, Erica Wagner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2010
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years oldMyron J Levin, Anna-Barbara Moscicki, Lin-Ye Song, et al.
The Journal of Infectious Diseases|April 5, 2018
Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897Qing Zhu, Bin Lu, Patrick McTamney, et al.
Journal of Immunological Methods|April 22, 2004
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assayDavid Opalka, Antonello Pessi, Elisabetta Bianchi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2008
An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virionsJoseph G Joyce, Isaac J Krauss, Hong C Song, et al.
The Journal of Infectious Diseases|January 23, 2023
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy AdultsPablo Forte-Soto, Muna Albayaty, Dennis Brooks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2024
Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)Doug Arbetter, Vancheswaran Gopalakrishnan, Anastasia A Aksyuk, et al.
Clinical and Diagnostic Laboratory Immunology|August 9, 2005
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18Dennis Dias, Jeff Van Doren, Sonela Schlottmann, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Science Translational Medicine|December 21, 2022
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccineLauren A Chang, Emily Phung, Michelle C Crank, et al.
The New England Journal of Medicine|July 30, 2020
Single-Dose Nirsevimab for Prevention of RSV in Preterm InfantsM Pamela Griffin, Yuan Yuan, Therese Takas, et al.
Clinical and Vaccine Immunology : CVI|March 27, 2009
Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigenMichael D Raedler, Samantha Heyne, Erica Wagner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2010
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years oldMyron J Levin, Anna-Barbara Moscicki, Lin-Ye Song, et al.
The Journal of Infectious Diseases|April 5, 2018
Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897Qing Zhu, Bin Lu, Patrick McTamney, et al.
Journal of Immunological Methods|April 22, 2004
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assayDavid Opalka, Antonello Pessi, Elisabetta Bianchi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2008
An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virionsJoseph G Joyce, Isaac J Krauss, Hong C Song, et al.
The Journal of Infectious Diseases|January 23, 2023
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy AdultsPablo Forte-Soto, Muna Albayaty, Dennis Brooks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2024
Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)Doug Arbetter, Vancheswaran Gopalakrishnan, Anastasia A Aksyuk, et al.
Clinical and Diagnostic Laboratory Immunology|August 9, 2005
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18Dennis Dias, Jeff Van Doren, Sonela Schlottmann, et al.
Pageof 10